Please login to the form below

Not currently logged in

ABPI appoints head of commercial affairs

Carol Blount has joined the Association of the British Pharmaceutical Industry as head of commercial affairs

Carol Blount has joined the Association of the British Pharmaceutical Industry (ABPI) as head of commercial affairs.

She joins the ABPI with more than 15 years' senior level leadership experience within UK pharma including leadership of strategic innovation and change, business development and brand marketing. She has worked previously for Bayer and AstraZeneca.


Carol Blount
Carol Blount


In her new role, she is responsible for managing all commercial affairs and initiatives within the ABPI, including NHS Joint Working and quality innovation, prevention and productivity (QIPP) initiatives, delivery of commercial aspects of Pharmaceutical Price Regulation Scheme (PPRS), supply chain and distribution initiatives.

Carol commented: "With a new government and an uncertain financial situation throughout the world, these are challenging times for our industry. I am very much looking forward to working in my new role to help tackle some of the vitally important issues facing the industry."

Alison Clough, ABPI Commercial and Communications director said: "I am delighted that Carol is joining our strengthened commercial team. Her extensive experience will bring added value to our activities working with the NHS on QIPP, as well as supply shortages and other commercial issues."

15th June 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...